Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Immune checkpoints, such as Programmed Death 1 (PD-1), regulate T cell activity and can be exploited by tumors.
• Tumor cells expressing Programmed Death Ligand 1 (PD-L1) can suppress anti-tumor T cell responses.
• High PD-L1 expression in tumors is associated with poorer clinical outcomes in various cancers.

Purpose of the Study:

• To evaluate the efficacy and tolerability of blocking the PD-1/PD-L1 pathway in cancers.
• To assess the impact of PD-1/PD-L1 pathway inhibitors on treatment approaches for renal cell carcinoma (RCC) and melanoma.

Main Methods:

• Utilizing antibodies to block the interaction between PD-1 and PD-L1.
• Clinical evaluations of PD-1/PD-L1 pathway-blocking agents in patients with RCC and melanoma.

Main Results:

• Antibodies targeting the PD-1/PD-L1 pathway demonstrate efficacy in RCC and melanoma.
• Objective response rates of over 30% in RCC and 50% in melanoma patients were observed.
• Durable responses are achievable, even after treatment discontinuation.
• Generally manageable inflammatory toxicities were noted.

Conclusions:

• PD-1/PD-L1 pathway blockade represents a promising therapeutic strategy for RCC and melanoma.
• These agents have the potential to significantly change the treatment landscape for these deadly cancers.
• Further investigation into PD-1/PD-L1 pathway inhibitors is warranted for advanced RCC and melanoma.